Skip to content
  • Investors
    • Overview
    • News
    • Events and Presentations
    • Stock Info
    • Financials
    • Governance
    • Resources
  • Join Us
Femasys Logo
  • About Us
    • Overview
    • Leadership
    • Board of Directors
  • Our Focus
  • Our Pipeline
    • Portfolio
    • Clinical Stage
    • Commercial
  • Resources
  • Contact Us
  • About Us
    • Overview
    • Leadership
    • Board of Directors
  • Our Focus
  • Our Pipeline
    • Portfolio
    • Clinical Stage
    • Commercial
  • Resources
  • Contact Us
  • Investors
    • Overview
    • News
    • Events and Presentations
    • Stock Info
    • Financials
    • Governance
    • Resources
  • Join Us
Femasys Logo
  • About Us
    • Overview
    • Leadership
    • Board of Directors
  • Our Focus
  • Our Pipeline
    • Portfolio
    • Clinical Stage
    • Commercial
  • Resources
  • Contact Us
  • Investors
    • Overview
    • News
    • Events and Presentations
    • Stock Info
    • Financials
    • Governance
    • Resources
  • Join Us

Media

FemCerv®: Well-designed technology that can minimize patient discomfort

2023, Media / By lsc-webmaster

The Post-Roe Fertility Journey

2023, Media / By lsc-webmaster

US biomedical company launches intrauterine device for tubal evaluation

2023, Media / By lsc-webmaster

Femasys Selected by BioSpace as a 2023 Best Places to Work

2022, Media / By lsc-webmaster

Femasys Targets Male Infertility with Updated Trial Design

2022, Media / By lsc-webmaster

Femasys Inc. Provides Strategic Update on its FemaSeed® Pivotal Trial Design to Expedite Clinical Program Advancement

2022, Media / By lsc-webmaster

Femasys Inc. Announces the Appointment of Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs

2022, Media / By lsc-webmaster

Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control

2022, Media / By lsc-webmaster

Femasys Inc. Announces the Commercial Availability of FemCerv® for Cervical Cancer Screening and Expands Management Team

2022, Media / By lsc-webmaster

Tech Companies Working On Contraception Face A New Landscape After Roe

2022, Media / By lsc-webmaster
Posts navigation
1 2 … 4 Next Page →

Recent Posts

  • FemCerv®: Well-designed technology that can minimize patient discomfort
  • The Post-Roe Fertility Journey
  • US biomedical company launches intrauterine device for tubal evaluation
  • Femasys Selected by BioSpace as a 2023 Best Places to Work
  • Femasys Targets Male Infertility with Updated Trial Design

Recent Comments

No comments to show.

Archives

  • April 2023
  • February 2023
  • January 2023
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • February 2022
  • January 2022
  • December 2021
  • October 2021
  • July 2021
  • June 2021
  • May 2021

Categories

  • 2021
  • 2022
  • 2023
  • Board of Directors
  • Leadership
  • Media
  • Video

Femasys Color Logo

  • Privacy & Terms
  • Patents
  • Accessibility

Copyright © 2023  Femasys Inc.

FemaSeed, FemBloc, FemCath, FemCerv, and FemVue are registered trademarks of Femasys Inc. FemEMB is a trademark of Femasys Inc.